Ipca Laboratories is expecting overall growth for FY14 and FY15 to be around 18-20%. Out of 18 products the company is currently able to supply only 8 products to the US due to capacity constraints. But now with expansion of capacity at the Indore facility, all the products have been taken in for commercialization, and the full utilization will take place over two years. The company is also looking at further expansion of capacity at Indore.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
